Vaccinex Stock Price, News & Analysis

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company focused on research and development in biotechnology, with an emphasis on slowly progressive neurodegenerative diseases and cancer. According to company disclosures, Vaccinex is pioneering a differentiated approach based on inhibition of semaphorin 4D (SEMA4D), a signaling molecule that the company believes plays a central role in neuroinflammation, astrocyte activation, and immune suppression in tumors.

The company’s lead drug candidate is pepinemab, a humanized IgG4 monoclonal antibody designed to block SEMA4D. Vaccinex states that SEMA4D can bind to plexin-B1 receptors, triggering collapse of the actin cytoskeleton and loss of homeostatic functions in astrocytes and other glial cells in the brain, as well as dendritic cells in immune tissue. By blocking this pathway, pepinemab is being investigated as a potential treatment for Alzheimer’s disease (AD), Huntington’s disease (HD), and several solid tumor cancers, including head and neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma (PDAC).

Core therapeutic focus and pipeline

In neurodegenerative disease, Vaccinex reports that pepinemab has been studied as a monotherapy in the randomized Phase 1b/2 SIGNAL-AD trial in patients with Mild Cognitive Impairment (MCI) and mild dementia due to Alzheimer’s disease. Company communications describe treatment effects on biomarkers such as glial fibrillary acidic protein (GFAP) and phosphorylated tau peptide (p‑tau 217), which are associated with astrocyte reactivity and tau pathology. Vaccinex has also previously conducted a randomized Phase 2 study of pepinemab in Huntington’s disease and has reported evidence suggesting a slowing of cognitive decline in that indication.

In oncology, Vaccinex is evaluating pepinemab in combination with established immune checkpoint inhibitors. The company highlights the Phase 1b/2 KEYNOTE‑B84 study in recurrent or metastatic HPV‑negative head and neck cancer in collaboration with Merck Sharp & Dohme Corp (KEYTRUDA®), and a Phase 1b/2 study in metastatic pancreatic adenocarcinoma in combination with BAVENCIO® (avelumab). Vaccinex also notes several investigator‑sponsored studies of pepinemab in solid tumors, including breast cancer and melanoma. Across these programs, the company reports that pepinemab appears to induce or enhance tertiary lymphoid structures (TLS) in tumors and may improve the activity of immune checkpoint therapies, particularly in immunologically “cold” tumors such as HPV‑negative and PD‑L1‑low HNSCC.

Scientific approach and mechanism

Vaccinex’s scientific rationale centers on the role of SEMA4D in both the central nervous system and the tumor microenvironment. Company materials describe SEMA4D as a “potent biological effector” that:

• Triggers damaging inflammation in chronic diseases of the brain by promoting astrocyte reactivity and neuroinflammation.
• Prevents infiltration and activation of immune cells in tumors by inhibiting dendritic cell migration and maturation, limiting productive T‑cell responses.

Pepinemab is designed to block SEMA4D and thereby preserve normal astrocyte and dendritic cell functions. In neurodegenerative disease, Vaccinex reports that pepinemab treatment is associated with changes in biomarkers and cognitive measures in Alzheimer’s and Huntington’s disease. In oncology, the company describes data in melanoma and head and neck cancer suggesting that pepinemab can promote formation and maturation of TLS, which correlate with improved clinical outcomes when combined with checkpoint inhibitors.

Platform technology: ActivMAb®

Beyond pepinemab, Vaccinex has developed the ActivMAb® antibody discovery platform. According to the company, ActivMAb is a proprietary poxvirus‑based technology that enables expression of functional, properly folded complex membrane proteins such as G‑protein‑coupled receptors (GPCRs) and ion channels on a viral membrane. This provides a source of antigen for multiple antibody discovery strategies, including antibodies and antibody‑based immunotherapies. Vaccinex reports that ActivMAb has applications in discovery of antibodies specific for complex membrane antigens, optimization of antibody developability, and protein optimization for expression and activity.

The company has disclosed multiple project agreements with biopharmaceutical partners, including Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing ActivMAb to generate antibodies to complex targets. Vaccinex also supplies materials to partners such as Charles River Labs, OmniAb and Adimab to support their antibody discovery programs. The first clinical candidate selected using ActivMAb, CHS‑114 (a fully human monoclonal antibody targeting CCR8), is reported by Vaccinex to be in clinical development for cancer immunotherapy by Coherus Biosciences, Inc.

Regulatory and listing status

Vaccinex has described itself as a clinical‑stage biotechnology company, indicating that its lead programs are in human clinical trials rather than commercial stages. The company has reported that its common stock traded on The Nasdaq Capital Market under the symbol VCNX and later noted that trading on Nasdaq was suspended following a Nasdaq Hearings Panel decision to delist the shares for failure to meet continued listing standards related to stockholders’ equity. Vaccinex has stated that it expects or intends its common stock to be quoted on the OTC Markets Group under the symbol VCNX and has announced plans to file a Form 25 to remove its common stock from listing on Nasdaq. These disclosures indicate a transition from a national exchange listing to over‑the‑counter quotation, while the company continues its clinical and partnering activities.

Therapeutic areas and indications

Based on company statements, Vaccinex’s work is concentrated in the following therapeutic areas:

• Neurodegenerative diseases: Alzheimer’s disease (MCI and mild dementia stages), Huntington’s disease, and potential relevance to other conditions characterized by astrocyte activation and neuroinflammation.
• Oncology: Recurrent or metastatic head and neck squamous cell carcinoma (including HPV‑negative and PD‑L1‑low disease), metastatic pancreatic adenocarcinoma, melanoma, breast cancer, and other solid tumors studied in investigator‑sponsored trials.

Across these indications, Vaccinex emphasizes the potential of SEMA4D blockade to modulate glial and immune cell behavior, aiming to slow disease progression in neurodegeneration and enhance anti‑tumor immunity in cancer.

Collaborations and funding approach

Vaccinex reports that it holds global commercial and development rights to pepinemab and sponsors the KEYNOTE‑B84 study in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc. The company also notes collaborations with Merck KGaA, Darmstadt, Germany (BAVENCIO®) and multiple partners using the ActivMAb platform. In neurodegenerative disease, Vaccinex has disclosed support from organizations such as the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Association for the SIGNAL‑AD study.

In its communications, Vaccinex indicates that it plans to continue development of pepinemab in Alzheimer’s disease and cancer through partnerships, grants and other financing avenues, and has described revenue‑sharing and financing agreements related to advancing a Phase 2b clinical trial of pepinemab in Alzheimer’s disease.

Risk profile and development stage

As a clinical‑stage biotechnology company, Vaccinex’s programs remain subject to the uncertainties inherent in clinical research, regulatory review, and financing. The company’s public statements include forward‑looking language about potential benefits of pepinemab and the prospects for continued development, while also acknowledging risks related to clinical trial outcomes, regulatory approvals, dependence on its lead product candidate, and listing status of its common stock.

Frequently asked questions (FAQ)